Researchers at The Royal Melbourne Hospital are investigating several new treatments to specifically treat Fabry disease, as well as additional studies to document and monitor the manifestations of disease beyond basic medical care.
The purpose of this study is to determine whether etrolizumab is a safe and effective treatment in patients with moderate to severe active ulcerative colitis that have previously had an unsuccessful response to treatment with immunosuppressants (aka TNF inhibitors - medications that reduces the activation or efficacy of the immune system) such as azathioprine, 6-mercaptopurine, or methotrexate and/or corticosteroids and to see whether etrolizumab is more effective than adalimumab in treating ulcerative colitis.
Crohn’s disease is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgotinib, an experimental drug, is effective and safe in treating people with moderate to severe Crohn’s disease.
The REDUCE study is testing whether or not reducing the dosage of antipsychotic medication of people recovering from their first episode of psychosis can lead to them having better recovery outcomes.
This study aims to see how effective a new blood test (using a diagnostic test called EUROIMMUN biochip) is in diagnosing and monitoring autoimmune blistering skin diseases, in comparison to the standard blood test.
Participants will be asked to donate an additional sample of blood which will be used for research into genetic susceptibility to autoimmune blistering skin disease. Only one visit is required and this usually will occur at the time of your visit at The Royal Melbourne Hospital.
This post-market study involves collecting information for an already approved VNS device. This type of study is conducted for many medications or medical devices to get detailed information about the outcomes of people receiving an approved treatment.
People participating in this study must be deemed appropriate for VNS treatment by their treating doctors and be planned for surgery at The Royal Melbourne Hospital.
The purpose of this study is to better understand the following areas of health for people who receive VNS treatment:
- Anti-epileptic treatment and medication taken by people who have had a VNS device implanted
- Frequency and severity of seizures
- Quality of life and quality of sleep (reported through questionnaires)
- What types of healthcare services are being used
- Details of the settings used on the VNS device
This research project is testing a new treatment for locally advanced or metastatic ER-positive breast cancer. The new treatment is called venetoclax given in combination with fulvestrant and we we want to know whether adding venetoclax will add to the effectiveness of the fulvestrant.
Fulvestrant is a drug that is designed to bind to the oestrogen receptors, completely blocking the ability of oestrogen to attach to these receptors. This can help to slow down the growth of ER-positive breast cancer.
Venetoclax has been approved for treatment of a type of leukaemia. In this study, venetoclax is an experimental drug, which means health authorties have not approved it in combination with fulvestrant for the treatment of ER-positive breast cancer.
A new anti-epileptic-drug, called perampanel shows promise for being able to control and prevent seizures in patients with brain tumours. There are two separate studies in this project for patients with gliomas, a type of brain tumour.